3.0T 31P磁共振波谱在评估慢性丙型肝炎抗病毒治疗反应中的应用
3.0T 31P MR spectroscopy in assessment of response to antiviral therapy for chronic hepatitis C.
作者信息
Zhang Chun-Yu, Zhang Qian, Zhang Hui-Mao, Yang Hai-Shan
机构信息
Chun-Yu Zhang, Hai-Shan Yang, Department of Radiology, China-Japan Union Hospital Affiliated to Jilin University, Changchun 130033, Jilin Province, China.
出版信息
World J Gastroenterol. 2014 Feb 28;20(8):2107-12. doi: 10.3748/wjg.v20.i8.2107.
AIM
To investigate the utility of phosphorus-31 (31P) magnetic resonance spectroscopy (MRS) as a noninvasive test for assessment of response to interferon and ribavirin treatment in patients with different severities of hepatitis C virus infection.
METHODS
Sixty chronic hepatitis C patients undergoing antiviral therapy with interferon and ribavirin underwent 31P MRS at 3.0T before treatment, 6 mo after the start of treatment, and 1 year after the start of treatment.
RESULTS
The phosphomonoester (PME)/phosphodiester (PDE) ratio at 6 mo after the start of antiviral therapy in the Child-Pugh B and C groups were significantly higher than those before therapy, but this was not seen in the Child-Pugh A group. In the antiviral therapy group, the PME/PDE ratios had decreased on follow-up MR spectroscopy. However, in the virological nonresponder group, the PME/PDE ratios on follow-up imaging were similar to the baseline values.
CONCLUSION
31P MRS can be used to provide biochemical information on hepatic metabolic processes. This study indicates that the PME/PDE ratio can be used as an indicator of response to antiviral treatment in chronic hepatitis C patients.
目的
探讨磷-31（31P）磁共振波谱（MRS）作为一种非侵入性检测方法，用于评估不同严重程度丙型肝炎病毒感染患者对干扰素和利巴韦林治疗反应的效用。
方法
60例接受干扰素和利巴韦林抗病毒治疗的慢性丙型肝炎患者在治疗前、治疗开始后6个月和治疗开始后1年接受了3.0T的31P MRS检查。
结果
抗病毒治疗开始后6个月，Child-Pugh B级和C级组的磷酸单酯（PME）/磷酸二酯（PDE）比值显著高于治疗前，但Child-Pugh A级组未出现这种情况。在抗病毒治疗组中，随访磁共振波谱时PME/PDE比值下降。然而，在病毒学无应答组中，随访成像时的PME/PDE比值与基线值相似。
结论
31P MRS可用于提供肝脏代谢过程的生化信息。本研究表明，PME/PDE比值可作为慢性丙型肝炎患者抗病毒治疗反应的指标。
Zotero 插件